Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Kα inhibitors

PI3Kα inhibitors have shown clinical activity in PIK3CA-mutated estrogen receptor-positive (ER+) breast cancer patients. Using whole genome CRISPR/Cas9 sgRNA knockout screens, we identified and validated several negative regulators of mTORC1 whose loss confers resistance to PI3Kα inhibition. Among t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Res
Hauptverfasser: Cai, Yanyan, Xu, Guotai, Wu, Fan, Michelini, Flavia, Chan, Carmen, Qu, Xuan, Selenica, Pier, Ladewig, Erik, Castel, Pau, Cheng, Yuanming, Zhao, Alison, Jhaveri, Komal, Toska, Eneda, Jimenez, Marta, Jacquet, Alexandra, Tran-Dien, Alicia, Andre, Fabrice, Chandarlapaty, Sarat, Reis-Filho, Jorge S., Razavi, Pedram, Scaltriti, Maurizio
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8137641/
https://ncbi.nlm.nih.gov/pubmed/33685991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-3232
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge